Results 151 to 160 of about 6,510 (202)

Efficacy and safety of azvudine versus nirmatrelvir/ritonavir in cancer patients with COVID-19. [PDF]

Sci Rep
Jia B, Sun J, Zhu D, Wang L, Hu X, Wang H, Qian G, Zhang D, Li S, Luo H, Zhang S, Li G, Li G, Liang H, Yu Z, Ren Z.   +15 more
europepmc   +1 more source

Clinical Characteristics and Treatment Efficacy in Patients With SARS-CoV-2 Positivity After Nirmatrelvir-Ritonavir Therapy. [PDF]

J Med Virol
Yang H, Gao L, Xue Y, Zhang Z, Guan L, Zhang H, Ma H, Li X, Li J, Tong Z.   +9 more
europepmc   +1 more source

Symptom Alleviation/Resolution and Returns to Usual Health/Activities in Immunocompromised Adults with COVID-19 Treated with Nirmatrelvir-Ritonavir: Results from the EPIC-IC Trial. [PDF]

Infect Dis Ther
Mokgokong R, Cislo P, Tudone E, Weinstein E, Cappelleri JC.   +4 more
europepmc   +1 more source

Paxlovid-induced Tacrolimus Toxicity in a Renal Transplant Recipient [PDF]

Doughty, Reece
core  

Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir.

JAMA
Mafi JN, Vangala S, Kapral MK, Wu PE, Cui M, Romanov A, Kahn KL.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +7 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2023
  +9 more sources

Nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +2 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2022
  +4 more sources